The potential for immunotherapy in melanoma has been demonstrated by improved outcomes among patients with stage III melanoma receiving interferon-α2b [4] and patients with metastatic melanoma receiving the anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody ipilimumab alone or in combination with a gp100 peptide vaccine or dacarbazine [5,6], as well as by durable complete responses with high-dose interleukin-2 [7] and high response rates after adoptive T cell transfer therapies [8]. Here, CTLA4 is linked to melanoma.